IBEC supports the accessibility to EU funded research results on COVID19
IBEC has signed the European Commission Manifesto for maximizing the accessibility of research results in the fight against COVID19
.
.
Under the name of “Modern approaches for developing antivirals against SARS-CoV 2” (MAD-CoV 2) the project focuses on the development and delivery of therapeutic tools for the current COVID-19 outbreak.
Now, Riccardo Levato, former researcher at IBEC, has been awarded with an ERC starting grant at UMC Utrecht to develop his project named “VOLUME-BIO”.
In this sense, the IBEC laboratories have reopened the doors for the students participating in the “Bojos per la Bioenginyeria” and the “Batx2Lab” programs, adapting to this “new normality”.
The results will be translated into a device that will recreate the tumor environment from cancer cells derived from patients, as well as a new technology that will allow to visualize how physical forces affect the nuclei of metastatic cells.
In a recent paper led by Ulm University in Germany and co-authored and co-led by Demestre, researchers describe the effect of SHANK3 protein on muscle tissues of patients with autism disorder.
Despite being preventable and treatable, malaria is an infectious disease that threatens the life of 3.2 billion people globally. Only in 2018, an estimated 228 million cases of malaria occurred worldwide, accounting for hundreds of thousands of deaths.
In total, ten researchers from the Catalan knowledge system (six men and four women) have received this distinction, as well as a research center that has been awarded the Narcís Monturiol Plaque, which recognizes an institution in the country.